
New Delhi, 19 November (H.S.): The Union Ministry of Health and Family Welfare has proposed introducing a separate licensing framework for the wholesale sale of bulk drugs, including active and inactive pharmaceutical ingredients. The ministry has issued a draft amendment to the Drugs Rules, 1945, for this purpose. Once implemented, the proposed changes will make it mandatory for wholesalers dealing in bulk drugs to obtain a separate licence through a dedicated application process. The move is aimed at enhancing accountability across the pharmaceutical supply chain and strengthening regulatory oversight of drug distribution.
Under Draft Gazette Notification No. G.S.R. 987(E), issued by the ministry on November 2, the government has proposed introducing a new application form, Form 19-BC, and a corresponding licence, Form 20-BC. Under the existing framework, a single licence permits the wholesale distribution of both drug formulations and bulk drugs. The proposed amendments seek to establish separate licensing provisions for these two categories.
Under the proposed framework, wholesalers will be required to specify in their licences the categories of bulk drugs they intend to trade in. This will also include medicines covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Furthermore, the sale and distribution of bulk drugs will have to take place under the personal supervision of a competent person. This provision is intended to ensure greater accountability in the handling, storage and distribution of such drugs.
According to the ministry, the separate licensing mechanism will facilitate more effective regulation of the wholesale bulk drug trade. It is also expected to strengthen efforts to address antimicrobial resistance (AMR), a growing public health concern arising when microorganisms develop resistance to antimicrobial medicines. The proposed framework will additionally help improve monitoring of the supply and movement of drugs regulated under the NDPS Act.
The proposal had earlier received approval at the 67th meeting of the Drugs Consultative Committee (DCC), held on November 17, 2025. Subsequently, it was also approved at the 93rd meeting of the Drugs Technical Advisory Board (DTAB) on February 16, 2026.
The ministry has also proposed a transition period to allow existing licence holders sufficient time to comply with the revised regulatory framework. For them, the new provisions will come into effect after the expiry of the retention period of their existing licences or 12 months from the final publication of the amended rules, whichever is later.
The Ministry of Health and Family Welfare has invited objections and suggestions from the general public and other stakeholders on the draft amendments. Interested individuals and stakeholders may submit their comments within 30 days from the date on which copies of the draft rules are made available to the public through the Gazette.
---------------
Hindusthan Samachar / Jun Sarkar